Literature DB >> 8534025

Hearing loss in Behçet's disease.

L Soylu1, B Aydoğan, M Soylu, C Ozsahinoğlu.   

Abstract

In order to determine the characteristics and incidence of hearing loss in Behçet's disease, 72 consecutive cases and 72 sex- and age-matched normal subjects were submitted to this study. Detailed audiologic tests were performed in all cases. Twenty patients (27%) showed some degree of hearing loss; but in only 7 patients (9%) was the average of the frequencies between 500 to 4,000 Hz more than 25 dB hearing level, and the cochlear function of 43 patients (59%) was within the 25-dB range in all frequencies. The averaged pure tone audiograms of the two groups showed a statistically significant hearing loss in the Behçet's group. No relationship could be found between hearing loss and other system involvements. There was no correlation between hearing loss and duration of the disease, but the mean age of the Behçet's patients with hearing loss was found to be significantly higher than the mean age of the patients without hearing loss.

Entities:  

Mesh:

Year:  1995        PMID: 8534025     DOI: 10.1177/000348949510401107

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  3 in total

1.  Vestibular evoked myogenic potentials in Behcet's disease.

Authors:  Seyra Erbek; Selim S Erbek; Sema Yilmaz; Eftal Yucel; Levent N Ozluoglu
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-03-26       Impact factor: 2.503

2.  Neurotological status in Behçet's disease and its ophthalmological correlates.

Authors:  Y A Bayazit; C Evereklioğlu; E Ozer; N Kirtak; N Bayazit; M Kanlikama; S Inalöz
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

Review 3.  Audiovestibular Symptoms in Systemic Autoimmune Diseases.

Authors:  Massimo Ralli; Vittorio D'Aguanno; Arianna Di Stadio; Armando De Virgilio; Adelchi Croce; Lucia Longo; Antonio Greco; Marco de Vincentiis
Journal:  J Immunol Res       Date:  2018-08-19       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.